Serum Thymidine Kinase 1 Activity in Solid Tumor (Breast and Colorectal Cancer) Patients Treated With Adjuvant Chemotherapy

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 3, 2013, Pages 220-226

  Bolayirli, M ^a   Papila, C ^a   Korkmaz, G G ^b   Papila, B ^a   Aydogan F ^a   Karatas A ^a   Uzun, H ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b KIRKLARELI UNIVERSITY   (Turkey)

Author keywords

Breast cancer; Chemotherapy; Colorectal cancer; Thymidine kinase activity

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; FOLIC ACID; OXALIPLATIN; THYMIDINE KINASE 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER ADJUVANT THERAPY; CELL PROLIFERATION; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG DOSE INCREASE; ENZYME ACTIVITY; FEMALE; HUMAN; MALE; SENSITIVITY AND SPECIFICITY;

ADULT; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; ROC CURVE; STATISTICS, NONPARAMETRIC; THYMIDINE KINASE;

EID: 84878022307     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21587     Document Type: Article

References (33)

1. Chen ZH, Huang SQ, Wang Y, et al. Serological thymidine kinase 1 is a biomarker for early detection of tumours-a health screening study on 35, 365 people, using a sensitive chemiluminescent dot blot assay. Sensors (Basel) 2011;11:11064-11080.
2. Kallander CF, Simonsson B, Hagberg H, Gronowitz JS. Serum deoxythymidine kinase gives prognostic information in chronic lymphocytic leukemia. Cancer 1984;54:2450-2455.
3. Hallek M, Wanders L, Strohmeyer S, Emmerich B. Thymidine kinase: A tumor marker with prognostic value for non-Hodgkin's lymphoma and a broad range of potential clinical applications. Ann Hematol 1992;65:1-5.
4. O'Neill KL Buckwalter MR, Murray BK. Thymidine kinase: Diagnostic and prognostic potential. Expert Rev Mol Diagn 2001;1:428-433.
5. Topolcan O, Holubec L, Jr. The role of thymidine kinase in cancer diseases. Expert Opin Med Diagn 2008;2:129-141.
6. Broet P, Romain S, Daver A, et al. Thymidine kinase as a proliferative marker: Clinical relevance in 1, 692 primary breast cancer patients. J Clin Oncol 2001;19:2778-2787.
7. Liu Y, Ling Y, Qi Q, et al. Changes in serum thymidine kinase 1 levels during chemotherapy correlate with objective response in patients with advanced gastric cancer. Exp Ther Med 2011;2:1177-1181.
8. Huang ZH, Tian XS, Li R, et al. Elevated thymidine kinase 1 in serum following neoadjuvant chemotherapy predicts poor outcome for patients with locally advanced breast cancer. Exp Ther Med 2012;3:331-335.
9. Gowda A, Byrd JC. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia. Curr Opin Hematol 2006;13:266-272.
10. Xu XH, Zhang YM, Shu XH, et al. Serum thymidine kinase 1 reflects the progression of pre-malignant and malignant tumors during therapy. Mol Med Report 2008;1:705-711.
11. von Euler H, Einarsson R, Olsson U, Lagerstedt AS, Eriksson S. Serum thymidine kinase activity in dogs with malignant lymphoma: A potent marker for prognosis and monitoring the disease. J Vet Intern Med 2004;18:696-702.
12. Sharif H, von Euler H, Westberg S, He E, Wang L, Eriksson S. A sensitive and kinetically defined radiochemical assay for canine and human serum thymidine kinase 1 (TK1) to monitor canine malignant lymphoma. Vet J 2012;194:40-47.
13. Carlsson L, Larsson A, Lindman H. Elevated levels of thymidine kinase 1 peptide in serum from patients with breast cancer. Ups J Med Sci 2009;114:116-120.
14. Nisman B, Allweis T, Kadouri L, et al. Comparison of diagnostic and prognostic performance of two assays measuring thymidine kinase 1 activity in serum of breast cancer patients. Clin Chem Lab 2012;51:439-447.
15. Luo P, He E, Eriksson S, et al. Thymidine kinase activity in serum of renal cell carcinoma patients is a useful prognostic marker. Eur J Cancer Prev 2009;18:220-224.
16. Pan ZL, Ji XY, Shi YM, Zhou J, He E, Skog S. Serum thymidine kinase 1 concentration as a prognostic factor of chemotherapy-treated non-Hodgkin's lymphoma patients. J Cancer Res Clin Oncol 2010;136:1193-1199.
17. Chen Y, Ying M, Chen Y, et al. Serum thymidine kinase 1 correlates to clinical stages and clinical reactions and monitors the outcome of therapy of 1, 247 cancer patients in routine clinical settings. Int J Clin Oncol 2010;15:359-368.
18. He E, Xu XH, Guan H, et al. Thymidine kinase 1 is a potential marker for prognosis and monitoring the response to treatment of patients with breast, lung, and esophageal cancer and non-Hodgkin's lymphoma. Nucleosides Nucleotides Nucleic Acids 2010;29:352-358.
19. Zou L, Zhang PG, Zou S, Li Y, He Q. The half-life of thymidine kinase 1 in serum measured by ECL dot blot: A potential marker for monitoring the response to surgery of patients with gastric cancer. Int J Biol Markers 2002;17:135-140.
20. He Q, Zhang P, Zou L, et al. Concentration of thymidine kinase 1 in serum (S-TK1) is a more sensitive proliferation marker in human solid tumors than its activity. Oncol Rep 2005;14:1013-1019.
21. Foekens JA, Romain S, Look MP, Martin PM, Klijn JG. Thymidine kinase and thymidylate synthase in advanced breast cancer: Response to tamoxifen and chemotherapy. Cancer Res 2001;61:1421-1425.
22. Svobodova S, Topolcan O, Holubec L, et al. Prognostic importance of thymidine kinase in colorectal and breast cancer. Anticancer Res 2007;27:1907-1909.
23. Li Z, Wang Y, Ma J, et al. Transient increase in serum thymidine kinase 1 within one week after surgery of patients with carcinoma. Anticancer Res 2010;30:1295-1299.
24. Zhang J, Jia Q, Zou S, et al. Thymidine kinase 1: A proliferation marker for determining prognosis and monitoring the surgical outcome of primary bladder carcinoma patients. Oncol Rep 2006;15:455-461.
25. Lee SJ, Kim SY, Chung JH, et al. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare. Biochem Pharmacol 2010;80:1528-1536.
26. Topolcan O, Holubec L, Jr, Finek J, et al. Changes of thymidine kinase (TK) during adjuvant and palliative chemotherapy. Anticancer Res 2005;25:1831-1833.
27. Nisman B, Allweis T, Kaduri L, et al. Serum thymidine kinase 1 activity in breast cancer. Cancer Biomark 2010;7:65-72.
28. Duffy MJ, Shering S, Sherry F, McDermott E, O'Higgins N. CA 15-3: A prognostic marker in breast cancer. Int J Biol Markers 2000;15:330-333.
29. Duffy MJ. Serum tumor markers in breast cancer: Are they of clinical value? Clin Chem 2006;52:345-351.
30. Elfagieh M, Abdalla F, Gliwan A, Boder J, Nichols W, Buhmeida A. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer. Tumour Biol 2012;33:2371-2377.
31. Mourtzikou A, Stamouli M, Kroupis C, et al. Evaluation of carcinoembryonic antigen (CEA), epidermal growth factor receptor (EGFR), epithelial cell adhesion molecule EpCAM (GA733-2), and carbohydrate antigen 19-9 (CA 19-9) levels in colorectal cancer patients and correlation with clinicopathological characteristics. Clin Lab 2012;58:441-448.
32. Lin PC, Lin JK, Lin CC, et al. Carbohydrate antigen 19-9 is a valuable prognostic factor in colorectal cancer patients with normal levels of carcinoembryonic antigen and may help predict lung metastasis. Int J Colorectal Dis 2012;27:1333-1338.
33. Fahmueller YN, Nagel D, Hoffmann RT, et al. Predictive and prognostic value of circulating nucleosomes and serum biomarkers in patients with metastasized colorectal cancer undergoing. Selective Internal Radiation Therapy. BMC Cancer 2012;12:5.